HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment. The clearance followed a successful ...

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced a commercial partnership with ClearCardio (TM), a preventive ...

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...

Sports cardiology has emerged as a distinct subspecialty at the intersection of preventive cardiology and athlete care. While ...

Romano-Ward syndrome, the most common congenital long QT disorder, often causes exertion- or stimulus-triggered syncope and ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced ...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it ...